Role of Helicobacter pylori virulence factors and alteration of the Tumor Immune Microenvironment: challenges and opportunities for Cancer Immunotherapy
Abstract Various forms of malignancies have been linked to Helicobacter pylori. Despite advancements in chemotherapeutic and surgical approaches, the management of cancer, particularly at advanced stages, increasingly relies on the integration of immunotherapy. As a novel, safe therapeutic modality, immunotherapy harnesses the immune system of the patient to treat cancer, thereby broadening treatment options. However, there is evidence that H. pylori infection may influence the effectiveness of immunotherapy in various types of cancer. This association is related to H. pylori virulence factors and the tumor microenvironment. This review discusses the influence of H. pylori infection on immunotherapy in non-gastrointestinal and gastrointestinal tumors, the mechanisms underlying this relationship, and directions for the development of improved immunotherapy strategies..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:206 |
|---|---|
| Enthalten in: |
Archives of microbiology - 206(2024), 4 vom: 15. März |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zhou, Junyi [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| BKL: | |
|---|---|
| Themen: |
| Anmerkungen: |
© The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
|---|
| doi: |
10.1007/s00203-024-03908-6 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR055139523 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR055139523 | ||
| 003 | DE-627 | ||
| 005 | 20240416064655.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240315s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00203-024-03908-6 |2 doi | |
| 035 | |a (DE-627)SPR055139523 | ||
| 035 | |a (SPR)s00203-024-03908-6-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 570 |q VZ |
| 084 | |a 42.30 |2 bkl | ||
| 100 | 1 | |a Zhou, Junyi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Role of Helicobacter pylori virulence factors and alteration of the Tumor Immune Microenvironment: challenges and opportunities for Cancer Immunotherapy |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. | ||
| 520 | |a Abstract Various forms of malignancies have been linked to Helicobacter pylori. Despite advancements in chemotherapeutic and surgical approaches, the management of cancer, particularly at advanced stages, increasingly relies on the integration of immunotherapy. As a novel, safe therapeutic modality, immunotherapy harnesses the immune system of the patient to treat cancer, thereby broadening treatment options. However, there is evidence that H. pylori infection may influence the effectiveness of immunotherapy in various types of cancer. This association is related to H. pylori virulence factors and the tumor microenvironment. This review discusses the influence of H. pylori infection on immunotherapy in non-gastrointestinal and gastrointestinal tumors, the mechanisms underlying this relationship, and directions for the development of improved immunotherapy strategies. | ||
| 650 | 4 | |a Immunotherapy |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Cancer |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Tumor microenvironment |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Virulence factor |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Zhang, Minna |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, HongGang |e verfasserin |4 aut | |
| 700 | 1 | |a Zhong, Xiaomin |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, XiaoZhong |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Archives of microbiology |d Springer Berlin Heidelberg, 1930 |g 206(2024), 4 vom: 15. März |w (DE-627)SPR001777815 |w (DE-600)1458451-7 |x 1432-072X |7 nnns |
| 773 | 1 | 8 | |g volume:206 |g year:2024 |g number:4 |g day:15 |g month:03 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s00203-024-03908-6 |m X:VERLAG |x 0 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 42.30 |q VZ |
| 951 | |a AR | ||
| 952 | |d 206 |j 2024 |e 4 |b 15 |c 03 | ||